Evidence map›Paper›PMID 39040169›Full record

ArticlemedRxiv : the preprint server for health sciences2024

Prevalence of the Cefazolin Inoculum Effect (CzIE) in Nasal Colonizing Methicillin-Susceptible

Lina P Carvajal, Sandra Rincon, Sara I Gomez-Villegas, Juan M Matiz-González, Karen Ordoñez, Alejandra Santamaria, Leonardo Ospina-Navarro, Jaime Beltran, Fredy Guevara, Yardany R Mendez and 12 more

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors.

Lina P CarvajalMolecular Genetics and Antimicrobial Resistance Unit, Universidad El Bosque, Bogota, Colombia.
Sandra RinconMolecular Genetics and Antimicrobial Resistance Unit, Universidad El Bosque, Bogota, Colombia.
Sara I Gomez-VillegasBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Juan M Matiz-GonzálezMolecular Genetics and Antimicrobial Resistance Unit, Universidad El Bosque, Bogota, Colombia.
Karen OrdoñezDepartment of Infectious Diseases, ESE Hospital Universitario, San Jorge de Pereira, Pereira, Colombia.
Alejandra SantamariaDepartment of Infectious Diseases, ESE Hospital Universitario, San Jorge de Pereira, Pereira, Colombia.
Leonardo Ospina-NavarroClinica Colsubsidio Calle 100, Bogota, Colombia.
Jaime BeltranClinica Colsubsidio Calle 100, Bogota, Colombia.
Fredy GuevaraServicio de Infectología, Fundación Santafe de Bogota, Bogota, Colombia.
Yardany R MendezGrupo de Investigacion en Epidemiologia Clinica de Colombia (GRECO), Universidad Pedagogica y Tecnologica de Colombia, Tunja, Colombia.
Soraya SalcedoOrganizacion Clinica General del Norte, Barranquilla, Colombia.
Alexandra PorrasLos Cobos Medical Center, Bogota, Colombia.
Albert Valencia-MorenoLos Cobos Medical Center, Bogota, Colombia.
Haley GrenniaCenter for Infectious Disease, Houston Methodist Research Institute, Houston, TX USA.
Alexander DeyanovCenter for Infectious Disease, Houston Methodist Research Institute, Houston, TX USA.
Rodrigo BaptistaCenter for Infectious Disease, Houston Methodist Research Institute, Houston, TX USA.ORCID 0000-0002-1806-8260
Vincent H TamDepartament of Pharmacy Practice and Translational Research, University of Houston, Houston, Texas, United States.
Diana PanessoMolecular Genetics and Antimicrobial Resistance Unit, Universidad El Bosque, Bogota, Colombia.
Truc T TranCenter for Infectious Disease, Houston Methodist Research Institute, Houston, TX USA.
William R MillerCenter for Infectious Disease, Houston Methodist Research Institute, Houston, TX USA.ORCID 0000-0002-1518-2973
Cesar A AriasCenter for Infectious Disease, Houston Methodist Research Institute, Houston, TX USA.
Jinnethe ReyesMolecular Genetics and Antimicrobial Resistance Unit, Universidad El Bosque, Bogota, Colombia.

Funding

Project 3: Functional Microbiome and Host Signatures in Transition from Commensal to pathogenP01AI152999 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI SAVIDGE, TOR C. · 2020 to 2025
$12.0M
VENOUS: A translational study of enterococcal bacteremiaR01AI148342 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2020 to 2024
$3.9M
The LiaFSR system and antimicrobial peptide resistance in enterococciR01AI134637 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Cesar Augusto Arias · 2018 to 2026
$3.7M
Clinical Impact of the Cefazolin Inoculum EffectR01AI173138 · NIAID · METHODIST HOSPITAL RESEARCH INSTITUTE · PI Cesar Augusto Arias · 2023 to 2026
$2.6M
POR Program on Genomic Prediction of Antimicrobial Resistance in VREK24AI121296 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2016 to 2025
$1.5M
NIAID NIH HHS K24 AI121296NIAID NIH HHS P01 AI152999NIAID NIH HHS R01 AI134637NIAID NIH HHS R01 AI148342NIAID NIH HHS R01 AI173138
6 · The paper itself

Abstract

The cefazolin inoculum effect (CzIE) has been associated with poor clinical outcomes in patients with MSSA infections. We aimed to investigate the point prevalence of the CzIE among nasal colonizing MSSA isolates from ICU patients in a multicenter study in Colombia (2019-2023). Patients underwent nasal swabs to assess for

Identifiers

PMID39040169
PMCPMC11261917

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.